DNA sequencing confirmed the presence of KRAS mutations, one of the most common driver mutations in lung adenocarcinoma, in three of the xenograft models and mutations in BRAF and NRAS, two less frequently occurring mutations associated with NSCLC[32], in two of the models. Here, KRAS is linked to non-small cell lung carcinoma.